Windward Bio Files S-1 for Nasdaq IPO
Windward Bio, a clinical-stage biotech focused on tumor microenvironment therapies, filed its S-1 registration with the SEC on October 26, 2026, initiating its Nasdaq IPO process. The company has no approved products and remains in preclinical/early clinical development.
51CFO view：For pre-revenue biotechs like Windward, the CFO must master SEC Staff Accounting Bulletin No. 121 on milestone payments, apply ASC 730 rigorously for R&D expense classification, and design financial disclosures that withstand scrutiny of clinical trial cost accruals and FDA engagement timelines.
Windward Bio, a clinical-stage biotech focused on tumor microenvironment therapies, filed its S-1 registration with the SEC on October 26, 2026, initiating its Nasdaq IPO process. The company has no approved products and remains in preclinical/early clinical development.
Source：Google News · 美股 IPO
Why this matters to your CFO search
Where this touches your finance hire
Every listing event changes what you need from a CFO. Start from the step you are actually at.
What kind of CFO does a US IPO need?
S-1 / F-1 filing, US GAAP conversion, roadshow — the hard requirements.
Read →
Who owns SEC reporting and US GAAP?
Signature responsibility for 10-K / 10-Q / 8-K / 20-F, and common comments.
Read →
Who runs finance through a SPAC merger?
De-SPAC files F-1 / 424(b); merger audit and disclosure cadence differ.
Read →